ABSTRACT Objective: This study was conducted to provide data about the survival rate of testicular cancer patients with different histology in the year 2013 – 2017 in Adam Malik General Hospital and to compare these estimates with other studies conducted in another center. Material & Methods: Medical records of testicular cancer patients from 2013 to 2017 in Adam Malik General Hospital were collected. We measured 5-year relative survival between the histology group of seminoma and non-seminoma estimated using Kaplan-Meier survival analysis. Also, using Kaplan-Meier for survival analysis estimated, 5-year relative survival between metastatic and non-metastatic was estimated. Results: 63 male patients (mean age 27.5 ± 17.6 years old) were included in this study. The distribution of histology were non-seminoma (53.9%), seminoma (39.9%), non-Hodgkin lymphoma (4.7%), and gonadoblastoma (1.5%). The 5-year relative survival rate was 82.5% for the seminoma group and 80.9 % for the non-seminoma group. The 5-year survival rate in the seminoma group with metastatic was 77.8% and in the non-metastatic group was 87.3 %. The 5-year survival rate in the non-seminoma group with metastatic was 74.6 % and in the non-metastatic group was 88.9 %. Conclusion: 5-year relative survival was better for the seminoma group than the non-seminoma group. Moreover, non-metastasis seminoma was found to have a better outcome than the metastatic group. Despite that, in the non-metastatic group, it is found that non-seminoma testicular cancer has a better survival rate than seminoma testicular cancer. Keywords: 5-year relative survival rate, seminoma, non-seminoma, testicular cancer.
5-year relative survival rate, seminoma, non-seminoma, testicular cancer
Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med. 1997; 337: 242.
Purdue MP, Devesa SS, Sigurdson AJ, McGlynn KA. International patterns and trends in testic cancer incidence. Int J Cancer. 2005; 115(5): 882-7.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer. 2014; 136(5): E359-E386.
Nigam M, Aschebrook-Kilfoy B, Shikanov S, Eggener S. Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009. World J Urol. 2015; 33(5): 623-31.
Smith ZL, Wentz RP, Eggener SE. Testicular cancer: epidemiology, diagnosis, and management. Med Clin N Am. 2018; 2(2): 251-264.
Park JS, Kim J, Elghiaty A, Ham WS. Recent global trends in testicular cancer incidence and mortality. Medicine. 2018; 97(37): pe12390.
Inci K, Dogan HS, Akdogan B, Ergen A, Tasar C, Ozen H. Does age affect the prognosis of patients with testicular germ cell tumor? Urol Int. 2007; 79(2): 117-123.
Fossa SD, Cvancarova M, Chen L, Allan AL, Oldenburg J, Peterson DR, et al. Adverse prognostic factors for testicular cancer-specific survival: a population-based study of 27,948 patients. J Clin Oncol. 2011; 29(8): 963-70.
Stang A, Jansen L, Trabert B, Rusner C, Eberle A, Katalinic A, et al. Survival after a diagnosis of testicular germ cell cancers in Germany and the United States, 2002-2006: A high resolution study by histology and age. Cancer Epidemiol. 2013; 37(4): 492-7.
Kvammen O, Myklebust TA, Solberg A, Moller B, Klepp OH, Fossa SD, et al. Long-term relative survival after diagnosis of testicular germ cell tumor. Cancer Epidemiology Biomarkers & Prevention. 2016; 25(5): 773-779.
Williamson S, Delahunt B, Magi-Galluzzi C, Algaba F, Egevad L, Ulbright T et al. The World Health Organization 2016 classification of testicular germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel. Histopathology. 2016; 70(3): 335-346.
Spermon JR, Witjes JA, Kiemeney LALM. Difference in stage and morphology-adjusted survival between young and elderly patients with a testicular germ cell tumor. Urology. 2002; 60(5): 889-893.